Maarten van der Doelen

Immunophenotyping during radium-223 therapy in mCRPC patients

A

CD3

CD4

CD8

20 30 40 50

30 40 50 60

40 50 60 70 80

10 CD3 + cells (%)

CD3 + cells (%)

Live PBMC (%)

BL 2 4 6

BL 2 4 6

BL 2 4 6

CTLA-4

ICOS

PD-1

PD-L1

TIM-1

TIM-3

B

5

90

30 40

1 2 CD4 + cells (%)

1 2

10

1 2

70 80

5

20

1 2

1 2

20 30 40 50

1 2

2 1

60 70 80

3

CD8 + cells (%)

BL 2 4

6

BL 2

4

6

BL 2 4

6

BL 2 4

6

BL 2 4

6

BL 2 4

6

C

CD45RO - CCR7 -

CD45RO + CCR7 -

CD45RO + CCR7 +

CD45RO - CCR7 -

CD45RO + CCR7 -

CD45RO + CCR7 +

2 1 5

30 40 50

20

20

40

40

10

30

CD4 + cells (%)

20 CD8 + cells (%)

10

30

5

BL 2 4 6

BL 2 4 6

BL 2 4 6

BL 2 4 6

BL 2 4 6

BL 2 4 6

CTLA-4

M-MDSC

D

Tregs

PD-L1

eMDSC

PD-L1

30 40 50 60 70 80

2 1

5 2 1 10

10

20 30 40

60 70 80 90

5 CD4 + cells (%)

Tregs (%)

10 eMDSC (%)

M-MDSC (%)

Live PBMC (%)

Live PBMC (%)

BL 2 4 6

BL 2 4 6

BL 2 4 6

BL 2 4 6

BL 2 4 6

BL 2 4 6

Injection number

Supplementary figure 7. Overview of the immune cell subsets in the alkaline phosphatase (ALP) responding subgroup throughout radium-223 treatment. A . CD3 + , CD4 + , and CD8 + T cells. B . Immune checkpoint expressing T cells. C . Memory and effector T cell subsets. D . Immunosuppressive cell subsets. Red dots indicate the group means. The blue line represents the fitted linear regression model, including 95% CI.

83